Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Galluzzo

Showing results (61-70 of 111) with videos related to

Pageof 12
Sort By:
Expert Opinion on Biological Therapy|December 10, 2020
<i>HLA-Cw6</i> and other HLA-C alleles, as well as <i>MICB-DT, DDX58,</i> and <i>TYK2</i> genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasisMartina Morelli, Marco Galluzzo, Stefania Madonna, et al.
Expert Opinion on Biological Therapy|April 1, 2026
Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experienceAngelo Ruggiero, Martina Burlando, Anna Balato, et al.
Expert Opinion on Biological Therapy|October 5, 2021
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populationsMarco Galluzzo, Andrea Chiricozzi, Elisa Cinotti, et al.
Cell Cycle (Georgetown, Tex.)|August 17, 2019
Skin immunity and its dysregulation in psoriasisCaterina Lanna, Mara Mancini, Roberta Gaziano, et al.
Pharmaceuticals (Basel, Switzerland)|April 28, 2023
A Real-Life Study on the Use of Tildrakizumab in Psoriatic PatientsElena Campione, Sara Lambiase, Ruslana Gaeta Shumak, et al.
The Journal of Dermatological Treatment|February 23, 2026
Toward the definition of moderate psoriasis: an expert opinionAntonio Costanzo, Federico Bardazzi, Martina Burlando, et al.
Italian Journal of Dermatology and Venereology|May 23, 2024
Anti-Herpes zoster vaccination in patients with dermatologic diseases: a position statement from the Italian SIDeMaST group of sexually transmitted, infectious and tropical diseasesGiulia Ciccarese, Francesco Drago, Astrid Herzum, et al.
Clinical Rheumatology|January 6, 2018
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric studyMaria Sole Chimenti, Augusta Ortolan, Mariagrazia Lorenzin, et al.
The Journal of Dermatology|April 3, 2020
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkersSara Mazzilli, Caterina Lanna, Carlo Chiaramonte, et al.
Melanoma Research|July 17, 2025
Peripheral blood inflammation indexes correlate with advanced stages in cutaneous melanoma: a single-center retrospective studyCosimo Di Raimondo, Angela Fico, Mariagrazia Cicala, et al.
Pageof 12

Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
Expert Opinion on Biological Therapy|December 10, 2020
<i>HLA-Cw6</i> and other HLA-C alleles, as well as <i>MICB-DT, DDX58,</i> and <i>TYK2</i> genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasisMartina Morelli, Marco Galluzzo, Stefania Madonna, et al.
Expert Opinion on Biological Therapy|April 1, 2026
Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experienceAngelo Ruggiero, Martina Burlando, Anna Balato, et al.
Expert Opinion on Biological Therapy|October 5, 2021
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populationsMarco Galluzzo, Andrea Chiricozzi, Elisa Cinotti, et al.
Cell Cycle (Georgetown, Tex.)|August 17, 2019
Skin immunity and its dysregulation in psoriasisCaterina Lanna, Mara Mancini, Roberta Gaziano, et al.
Pharmaceuticals (Basel, Switzerland)|April 28, 2023
A Real-Life Study on the Use of Tildrakizumab in Psoriatic PatientsElena Campione, Sara Lambiase, Ruslana Gaeta Shumak, et al.
The Journal of Dermatological Treatment|February 23, 2026
Toward the definition of moderate psoriasis: an expert opinionAntonio Costanzo, Federico Bardazzi, Martina Burlando, et al.
Italian Journal of Dermatology and Venereology|May 23, 2024
Anti-Herpes zoster vaccination in patients with dermatologic diseases: a position statement from the Italian SIDeMaST group of sexually transmitted, infectious and tropical diseasesGiulia Ciccarese, Francesco Drago, Astrid Herzum, et al.
Clinical Rheumatology|January 6, 2018
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric studyMaria Sole Chimenti, Augusta Ortolan, Mariagrazia Lorenzin, et al.
The Journal of Dermatology|April 3, 2020
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkersSara Mazzilli, Caterina Lanna, Carlo Chiaramonte, et al.
Melanoma Research|July 17, 2025
Peripheral blood inflammation indexes correlate with advanced stages in cutaneous melanoma: a single-center retrospective studyCosimo Di Raimondo, Angela Fico, Mariagrazia Cicala, et al.
Pageof 12